A comparative analysis presented at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting showed that FAPI PET/CT is more accurate in staging newly diagnosed breast cancer patients compared to 18F-FDG PET/CT. FAPI PET/CT restaged nearly 20% of patients, indicating its efficacy and benefits for clinical practice. The study included 121 patients, and FAPI PET/CT upstaged 21.7% of stage IIA patients who were initially staged by 18F-FDG PET/CT. The researchers believe that FAPI PET/CT has the potential to advance personalized treatment strategies for breast cancer patients by reducing unnecessary treatments and improving outcomes.
Tue, 11 Jun 2024 16:30:02 GMT | EurekAlert